Page 583 - Clinical Immunology_ Principles and Practice ( PDFDrive )

560 ParT fOur Immunological Deficiencies

Please check your eBook at https://expertconsult.inkling.com/ 23. Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr
for self-assessment questions. See inside cover for registration 2010;55:S102–5.
details. 24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines
for the use of antiretroviral agents in HIV-1-infected adults and
adolescents. Bethesda, MD: NIH Office of the AIDS Research Advisory
REFERENCES Council; 2011.
25. Violari A, Cotton M, Gibb D, et al. Early antiretroviral therapy and
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact Sheet mortality among HIV-infected infants. N Engl J Med 2008;359:2233–44.
2015. [3/29/2016]. Available at: http://www.unaids.org/en/resources/ 26. Panel on Antiretroviral Therapy and Medical Management of
campaigns/HowAIDSchangedeverything/factsheet. HIV-Infected Children. Guidelines for the use of antiretroviral agents in
2. UNICEF. Children & AIDS; 2015 Statistical update. New York: UNICEF; pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/
2015. Ivguidelines/pediatricguidelines.pdf. Accessed 2 July 2016.
3. Centers for Disease Control and Prevention. HIV Surveillance Report. 27. Nance CL, Siwak EB, Shearer WT. Preclinical development of the green
Atlanta, GA: CDC; 2014. p. 26. tea catechin, epigallocatechin gallate, as an HIV-1 therapy. J Allergy Clin
4. Centers for Disease Control and Prevention. HIV among pregnant Immunol 2009;123:459–65.
women, infants and children. 2016. [3/29/2016]. Available at: http:// 28. Azzoni L, Barbour R, Papasavvas E, et al. Early ART results in greater
www.cdc.gov/hiv/pdf/group/gender/pregnantwomen/ immune reconstitution benefits in HIV-infected infants: working with
cdc-hiv-pregnant-women.pdf. data missingness in a longitudinal dataset. PLoS ONE 2015;10:e0145320.
5. Richer LE, Halperin J. Acute human immunodeficiency virus infection. 29. Boulougoura A, Sereti I. HIV infection and immune activation: the role
Am J Med Sci 2013;345:136–42. of coinfections. Curr Opin HIV AIDS 2016;11:191–200.
6. Keele BF, Estes JD. Barriers to mucosal transmission of immunodeficiency 30. Siberry GK, Leister E, Jacobson D, et al. Increased risk of asthma and
viruses. Blood 2011;118:839–46. atopic dermatitis in perinatally HIV-infected children and adolescents.
7. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, Clin Immunol 2012;142:201–8.
pathogenesis, treatment, and prevention. Lancet 2014;384:259–71. 31. Gingo MR, Wenzel SE, Steele C, et al. Asthma diagnosis and airway
8. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV bronchodilator response in HIV-infected individuals. J Allergy Clin
infection. Blood 2013;121:29–37. Immunol 2012;129:708–14.
9. Martin AR, Siliciano RF. Progress toward HIV eradication: Case reports, 32. Shearer WT, Jacobson D, Yu W, et al. Long-term pulmonary
current efforts, and challenges associated with cure. Annu Rev Med complications of perinatally hiv-infected youth. J Allergy Clin Immunol
2016;67:215–28. 2017;pii: S0091-6749(17):30336–6.
10. Bonsignori M, Zhou T, Sheng Z, et al. Maturation pathway from germline 33. White AB, Mirjahangir JF, Horvath H, et al. Antiretroviral interventions
to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell for preventing breast milk transmission of HIV. Cochrane Database Syst
2016;165:449–63. Rev 2014;(10):CD011323.
11. Centers for Disease Control and Prevention. HIV and injection drug use. 34. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART
2015. [3/29/2016]. Available at: http://www.cdc.gov/hiv/pdf/risk/ and further decline in mother-to-child HIV transmission rates,
cdc-hiv-idu-fact-sheet.pdf. 2000-2011. AIDS 2014;28:1049–57.
12. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child 35. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of
HIV transmission in resource-poor countries: translating research into Perinatal Transmission. Recommendations for use of antiretroviral drugs
policy and practice. JAMA 2000;283:1175–82. in pregnant HIV-1-infected women for maternal health and interventions
13. Meier A, Alter G, Frahm N, et al. My D88-dependent immune activation to reduce perinatal HIV transmission in the United States. 2016. Available
mediated by human immunodeficiency virus type 1-encoded toll- like at: https://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0.
receptor ligands. J Virol 2007;81:8180–91. Accessed 3 May 2016.
14. Gringhius SI, van der Vlist M, van den Berg LM, et al. HIV-1 exploits 36. Luzuriaga K, Mofenson LM. Challenges in the elimination of pediatric
innate signaling by TLR8 and DC-SIGN for productive infection of HIV-1 infection. New Engl J Med 2016;374:761–70. PubMed PMID:
dendritic cells. Nat Immunol 2010;II:419–28. 26933850.
15. Heigele A, Joas S, Regensburger K, et al. Increased susceptibility of CD4+ 37. Tobian AA, Kacker S, Quinn TC. Male circumcision: a globally relevant
T cells from elderly individuals to HIV-1 infection and apoptosis is but under-utilized method for the prevention of HIV and other sexually
associated with reduced CD4 and enhanced CXCR4 and FAS surface transmitted infections. Annu Rev Med 2014;65:293–306.
expression levels. Retrovirology 2015;12:86. 38. Huang Y, Follmann D, Nason M, et al. Effect of rAd5-vector HIV-1
16. Campbell GR, Bruckman RS, Chu YL, et al. Autophagy induction by preventive vaccines on HIV-1 acquisition: a participant-level
histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem meta-analysis of randomized trials. PLoS ONE 2015;10:e0136626.
2015;290:5028–40. 39. Corey L, Gilbert PB, Tomaras GD, et al. Immune correlates of vaccine
17. Tomescu C, Abdulhaqq S, Montaner LJ. Evidence for the innate immune protection against HIV-1 acquisition. Sci Transl Med 2015;7:310rv7.
response as a correlate of protection in human immunodeficiency virus 40. Mylvaganam GH, Silvestri G, Amara RR. HIV therapeutic vaccines:
(HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp moving towards a functional cure. Curr Opin Immunol 2015;35:1–8.
Immunol 2011;164:158–69. 41. Byrareddy SN, Arthos J, Cicala C, et al. Sustained virologic control in
18. Scully E, Alter G. NK Cells in HIV Disease. Curr HIV/AIDS Rep SIV+ macaques after antiretroviral and α4β7 antibody therapy. Science
2016;13:85–94. 2016;354(6309):197–202.
19. Singh KK, Qin M, Brummel SS, et al. Killer cell immunoglobulin-like 42. Nishimura Y, Gautam R, Chun TW, et al. Early antibody therapy can
receptor alleles alter HIV disease in children. PLoS ONE 2016;11:e0151364. induce long-lasting immunity to SHIV. Nature 2017;543(7646):559–63.
20. Zhao L, Gao J, Li Y, et al. Disrupted homeostatic cytokines expression in 43. June CH, Levine BL. T cell engineering as therapy for cancer and HIV:
secondary lymph organs during HIV infection. Int J Mol Sci our synthetic future. Philos Trans R Soc Lond B Biol Sci
2016;17(3):pii: E413. 2015;370:20140374.
21. Fidler S, Fox J. Primary HIV infection: a medical and public health 44. Hutter G, Nowak D, Mossner M, et al. Long-term control by CCR5 Delta
emergency requiring rapid specialist management. Clin Med (Lond) 32/Delta 32 stem-cell transplantation. N Engl J Med 2009;360:692–8.
2016;16:180–3.
22. Hersperger AR, Martin JN, Shin LY, et al. Increased HIV-specific CD8+
T-cell cytotoxic potential in HIV elite controllers is associated with T-bet
expression. Blood 2011;117:3799–808.